Minster Pharmaceuticals plc has close working relationships with internationally renowned scientists and clinicians in a number of therapeutic areas.

Their services to the Company include:

• Reviewing the quality and relevance of the scientific and technical information being used or proposed as the basis for the development of the company's compounds. 
• Reviewing mechanistic studies, research programs and the technical basis of applied programs. 
• Reviewing generic approaches to regulatory science, including guidelines governing the use of scientific and technical information in regulatory decisions. 
• Advising the company on broad scientific matters in science and technology.

The Company’s current focus on migraine is reflected in the identity of its advisers in this therapeutic area. These include:

• Professor Steve Silberstein, (Chairman, Neurology Advisory Board)

Professor of Neurology and Director, Jefferson Headche Centre, Thomas Jefferson University, Philadelphia, USA. Past President American Headache Academy of Neurology.

•  Professor Andrew Charles

Professor of Neurology. Director of Headache Research and Treatment Program, David Geffen School of Medicine, UCLA, USA.

• Professor Carl Dahlof

Professor and Medical Director and founder of the Gothenburg Migraine Clinic Gothenberg, Sweden.

• Professor Paul Durham

Director, Centre for Biomedical and Life Sciences; Associate Professor, Cell Biology Missouri State University, USA.

• Professor Michel Ferrari

Professor, Department of Neurology, Leiden University Medical Centre, Netherlands.

• Professor Peter Goadsby

Professor of Clinical Neurology, Institute of Neurology, UK Headache Research Unit, Professor of Neurology, Dept of Neurology, University of California, San Francisco, USA.
Consultant Neurologist, University College, London.

• Professor Richard Lipton

Chair of Neurology, Professor of Epidemiology and Population Health, Albert Einstein College of Medicine, New York. Past President of the American Headache Society.

• Professor Jes Olesen

Professor,  University of Copenhagen and Chief of Danish Headache Centre, Department of Neurology, Glostrup University Hospital, Copenhagen, Denmark. Past President of IHS.

• Professor Michael Oshinsky

Research Assistant Professor of Technology and Director, Preclinical Research, Jefferson Headache Centre, Philadelphia, USA.

The Company’s advisers for its development programme with sabcomeline in schizophrenia include:

• Professor Herb Meltzer

Professor of Psychiatry & Pharmacology, Vanderbilt University, ACNP, Nashville, Tennessee USA.

•  Professor Jeffrey Lieberman

Chairman of Psychiatry, Columbia University College of Physicians and Surgeons and Director of the New York, USA State Psychiatric Institute.